• 1
    Hortobagyi GN. Trastuzumab in the treatment of breast cancer. N Engl J Med 2005; 353: 17346.
  • 2
    Puglisi F, Piccart M. Trastuzumab and breast cancer. Are we just beyond the prologue of a fascinating story? Onkologie 2005; 28: 5479.
  • 3
    Duesberg P, Rausch C, Rasnick D, Hehlmann R. Genetic instability of cancer cells is proportional to their degree of aneuploidy. Proc Natl Acad Sci USA 1998; 95: 136927.
  • 4
    Ormandy CJ, Musgrove EA, Hui R, Daly RJ, Sutherland RL. Cyclin D1, EMS1 and 11q13 amplification in breast cancer. Breast Cancer Res Treat 2003; 78: 32335.
  • 5
    Gillett C, Fantl V, Smith R, Fisher C, Bartek J, Dickson C, Barnes D, Peters G. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 1994; 54: 18127.
  • 6
    Lu C, Dong J, Ma H, Jin G, Hu Z, Peng Y, Guo X, Wang X, Shen H. CCND1 G870A polymorphism contributes to breast cancer susceptibility: a meta-analysis. Breast Cancer Res Treat 2008; 116: 5715.
  • 7
    Justenhoven C, Pierl CB, Haas S, Fischer HP, Hamann U, Baisch C, Harth V, Spickenheuer A, Rabstein S, Vollmert C, Illig T, Pesch B, et al. Polymorphic loci of E2F2, CCND1 and CCND3 are associated with HER2 status of breast tumors. Int J Cancer 2009; 124: 207781.
  • 8
    Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G. Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev 1993; 7: 81221.
  • 9
    Prall OW, Rogan EM, Musgrove EA, Watts CK, Sutherland RL. c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry. Mol Cell Biol 1998; 18: 4499508.
  • 10
    Zwijsen RM, Wientjens E, Klompmaker R, van der Sman J, Bernards R, Michalides RJ. CDK-independent activation of estrogen receptor by cyclin D1. Cell 1997; 88: 40515.
  • 11
    Neuman E, Ladha MH, Lin N, Upton TM, Miller SJ, DiRenzo J, Pestell RG, Hinds PW, Dowdy SF, Brown M, Ewen ME. Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4. Mol Cell Biol 1997; 17: 533847.
  • 12
    Bahr G, Gilbert F, Balaban G, Engler W. Homogeneously staining regions and double minutes in a human cell line: chromatin organization and DNA content. J Natl Cancer Inst 1983; 71: 65761.
  • 13
    Zimonjic DB, Zhang H, Shan Z, Factor V, Trent J, Thorgeirsson SS, Popescu NC. DNA amplification associated with double minutes originating from chromosome 19 in mouse hepatocellular carcinoma. Cytogenet Cell Genet 2001; 93: 1146.
  • 14
    Schwartsmann G, Madan K, Heins Y, Pinedo HM, Leyva A. Double-minute chromatin bodies in HL-60 leukemia cells sensitive and resistant to differentiation inducing agents. Cell Biol Int Rep 1987; 11: 6515.
  • 15
    Benner SE, Wahl GM, Von Hoff DD. Double minute chromosomes and homogeneously staining regions in tumors taken directly from patients versus in human tumor cell lines. Anticancer Drugs 1991; 2: 1125.
  • 16
    Meyers MB, Spengler BA, Chang TD, Melera PW, Biedler JL. Gene amplification-associated cytogenetic aberrations and protein changes in vincristine-resistant Chinese hamster, mouse, and human cells. J Cell Biol 1985; 100: 58897.
  • 17
    Schwab M. Oncogene amplification in solid tumors. Semin Cancer Biol 1999; 9: 31925.
  • 18
    Fridlyand J, Snijders AM, Ylstra B, Li H, Olshen A, Segraves R, Dairkee S, Tokuyasu T, Ljung BM, Jain AN, McLennan J, Ziegler J, et al. Breast tumor copy number aberration phenotypes and genomic instability. BMC Cancer 2006; 6: 96.
  • 19
    Yoshimoto M, Caminada De Toledo SR, Monteiro Caran EM, de Seixas MT, de Martino Lee ML, de Campos Vieira Abib S, Vianna SM, Schettini ST, Anderson Duffles Andrade J. MYCN gene amplification. Identification of cell populations containing double minutes and homogeneously staining regions in neuroblastoma tumors. Am J Pathol 1999; 155: 143943.
  • 20
    Albertson DG. Gene amplification in cancer. Trends Genet 2006; 22: 44755.
  • 21
    Cahill DP, Lengauer C, Yu J, Riggins GJ, Willson JK, Markowitz SD, Kinzler KW, Vogelstein B. Mutations of mitotic checkpoint genes in human cancers. Nature 1998; 392: 3003.
  • 22
    Wang TL, Rago C, Silliman N, Ptak J, Markowitz S, Willson JK, Parmigiani G, Kinzler KW, Vogelstein B, Velculescu VE. Prevalence of somatic alterations in the colorectal cancer cell genome. Proc Natl Acad Sci USA 2002; 99: 307680.
  • 23
    Buckley MF, Sweeney KJ, Hamilton JA, Sini RL, Manning DL, Nicholson RI, deFazio A, Watts CK, Musgrove EA, Sutherland RL. Expression and amplification of cyclin genes in human breast cancer. Oncogene 1993; 8: 212733.
  • 24
    Musgrove EA, Lee CS, Buckley MF, Sutherland RL. Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle. Proc Natl Acad Sci USA 1994; 91: 80226.
  • 25
    Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 11845.
  • 26
    Duffy MJ. Predictive markers in breast and other cancers: a review. Clin Chem 2005; 51: 494503.
  • 27
    Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham prognostic index in primary breast cancer. Breast Cancer Res Treat 1992; 22: 20719.
  • 28
    Detre S, Saclani Jotti G, Dowsett M. A “quickscore” method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol 1995; 48: 8768.
  • 29
    Camp RL, Neumeister V, Rimm DL. A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers. J Clin Oncol 2008; 26: 56307.
  • 30
    Bostner J, Ahnstrom Waltersson M, Fornander T, Skoog L, Nordenskjold B, Stal O. Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer. Oncogene 2007; 26: 69977005.
  • 31
    Lundgren K, Holm K, Nordenskjold B, Borg A, Landberg G. Gene products of chromosome 11q and their association with CCND1 gene amplification and tamoxifen resistance in premenopausal breast cancer. Breast Cancer Res 2008; 10: R81.
  • 32
    Wang Y, Dean JL, Millar EK, Tran TH, McNeil CM, Burd CJ, Henshall SM, Utama FE, Witkiewicz A, Rui H, Sutherland RL, Knudsen KE, et al. Cyclin D1b is aberrantly regulated in response to therapeutic challenge and promotes resistance to estrogen antagonists. Cancer Res 2008; 68: 562838.